MISSISSAUGA, Ont. – Valeant Pharmaceuticals International is expanding its presence in Eastern Europe by acquiring Austrian generic drug company Gerot Lannach’s assets primarily in Russia for less than $185 million.
Gerot Lannach’s largest product is acetylsalicylic acid, a low dose aspirin. The acquired assets are also sold in other Commonwealth of Independent States countries including Kazakhstan and Uzbekistan.
The company said total sales of these products was about $55 million last year, up more than 20 per cent from 2010.
Valeant Pharmaceuticals (TSX:VRX), based in Mississauga, Ont., is paying less than three times the value of sales plus up to $20 million in prospective milestone payments, based upon future performance objectives.
Get weekly money news
The strategic partnership between the two companies includes a 10-year exclusive supply agreement for the products and the opportunity for Valeant to introduce other Gerot Lannach products into South East Asia and Latin America.
The companies will also explore opportunities for Gerot Lannach to obtain rights to Valeant products that are not marketed in Gerot Lannach territories, Valeant said.
The transaction is expected to close in the near future and be immediately accretive.
- Alberta tweaks carbon capture incentive program to allow grants during construction
- ‘Cash is king’: Why money is a popular holiday present for many Canadians
- Rancher says Alberta well cleanup fund a positive step — but litany of concerns remain
- What makes the Anthropic IPO so significant, and what is the ‘god share’?
Valeant chairman and CEO Michael Pearson said the acquisition of another branded generics portfolio in Russia complements the range of products obtained with the Sanitas transaction.
“We believe that the Russian market, with overall market growth projected to be approximately 15 per cent, provides an attractive investment opportunity for Valeant,” he stated.
Pearson added the company continues to seek other acquisitions in Central and Eastern Europe.
Valeant Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
On the Toronto Stock Exchange, Valeant shares increased seven cents at $54.34 in morning trading.
Comments
Want to discuss? Please read our Commenting Policy first.